 Factor Xa Inhibitors
"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
| Descriptor ID |
D065427
|
| MeSH Number(s) |
D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".
This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 3 | 4 | 7 | | 2014 | 1 | 6 | 7 | | 2015 | 2 | 4 | 6 | | 2016 | 5 | 4 | 9 | | 2017 | 7 | 4 | 11 | | 2018 | 5 | 5 | 10 | | 2019 | 8 | 3 | 11 | | 2020 | 10 | 5 | 15 | | 2021 | 9 | 8 | 17 | | 2022 | 1 | 3 | 4 | | 2023 | 1 | 3 | 4 | | 2024 | 4 | 2 | 6 | | 2025 | 5 | 2 | 7 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.
-
Cotiguala L, Przybylski A, Linberger L, Brokhof M, Kenyon N, Joyce C, Dierker M, Ferguson K, Rech MA, Trotter C, Aguirre O, Lopez-Soler RI. Apixaban Use Before Kidney Transplantation: Is Reversal Necessary? Pharmacotherapy. 2026 Oct; 46(10):e70200.
-
Canonico ME, Parr J, Debus ES, Nehler MR, Patel MR, Anand SS, Svet M, Hess CN, Capell WH, Ycas J, Chen J, Szarek M, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circ Cardiovasc Interv. 2026 May; 19(5):e015229.
-
Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 11 29; 406(10519):2551-2563.
-
Hogan S, Szarek M, Debus ES, Nehler M, Anand SS, Patel MR, Pap AF, Deng H, Hodge S, Haskell LP, Muehlhofer E, Berkowitz SE, Bauersachs RM, Bonaca MP. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. J Am Heart Assoc. 2025 11 04; 14(21):e039752.
-
Verheye S, Ferdinande B, Bennett J, Staico R, El-Jack S, Tonino PAL, Abizaid A, Buysschaert I, Scott D, Menon M, Wilkins G, McClean D, Kovarnik T, Christians U, Neylon A, Mehmedbegovic Z, Smits PC, Morice MC, Webster M. Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus. Catheter Cardiovasc Interv. 2025 Oct; 106(4):2770-2780.
-
Markovic N, Budde E, Evans CT, Finch D, Xia Y, Huo Z, Han JH, Rech MA. Time to hemostatic agent administration increases mortality in veterans with factor Xa inhibitor-related intracranial hemorrhage. Am J Emerg Med. 2025 12; 98:201-206.
-
Rech MA, Budde E, Evans CT, Finch D, Xia Y, Huo Z, Han JH. Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. Am J Emerg Med. 2025 11; 97:97-102.
-
Kurth LM, Marshall WA, Stone LE, Hirshman BR, Box K, Haines LN, Smith AM, Costantini TW, Berndtson AE. It's all in your head: Safety of weight-based, targeted enoxaparin prophylaxis in intracranial hemorrhage patients. Surgery. 2025 08; 184:109476.
-
Hanke P, Domingo ME, Salanio G, Ahmed K, Hu J, Hendricks K, Howard J, Hashimura T, Guiliano C, Haan BJ, Ng TH, Kelley D, Knight T, Koopman K, Obstoj M, Breeden T, Sirbu D, Romano M, Harpenau A, Konneker R, Acevedo J, Pan N, Edwin SB. Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study. J Thromb Thrombolysis. 2025 Mar; 58(3):380-390.
-
Blotske K, Patel T, Trujillo T, Marlar M, Lind S, Kramer H, Hassell K, Kiser TH. Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients. Clin Appl Thromb Hemost. 2025 Jan-Dec; 31:10760296251319961.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|